Tasanto - Company finances
|
EUR
|
2021
From: 2021-02-18
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|
|
Financial data
|
|||||
| Sales revenue | 383,890 | 853,732 | 683,025 | 925,343 | 1,250,563 |
| Profit before tax | 5,918 | 76,797 | 108,637 | 187,608 | 105,223 |
| Net profit | 1,940 | 65,276 | 92,340 | 155,452 | 80,259 |
| Equity | 4,840 | 70,116 | 162,455 | 223,707 | 89,967 |
| Liabilities | 162,396 | 89,653 | 220,983 | 249,290 | 415,094 |
| Non-current assets | 10,806 | 27,921 | 37,336 | 118,824 | 122,536 |
| Current assets | 156,193 | 132,729 | 342,551 | 353,619 | 379,427 |
| Total assets | 166,999 | 160,650 | 379,887 | 472,443 | 501,963 |
|
Taxes paid
|
|||||
| STI taxes | - | - | 28,371 | - | - |
| Social insurance contributions | - | - | - | - | 6,146 |
|
Financial indicators
|
|||||
| Revenue change y/y | - | +122.4% | -20.0% | +35.5% | +35.1% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 1.2% | 40.6% | 24.3% | 32.9% | 16.0% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 40.1% | 93.1% | 56.8% | 69.5% | 89.2% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 0.5% | 7.6% | 13.5% | 16.8% | 6.4% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 1.5% | 9.0% | 15.9% | 20.3% | 8.4% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 33.6 | 1.3 | 1.4 | 1.1 | 4.6 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 222,249 | 788,085 | 341,513 | 462,672 | 300,133 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Tasanto - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2026-05-17 | 2026-05-20 | 0.01 |
| 2025-11-18 | 2025-11-23 | 0.16 |
| 2025-10-23 | 2025-11-10 | 0.16 |
| 2025-08-28 | 2025-08-29 | 0.49 |
| 2025-08-19 | 2025-08-21 | 0.49 |
| 2025-07-24 | 2025-08-13 | 0.49 |
| 2025-04-16 | 2025-04-16 | 605.03 |
| 2024-10-24 | 2024-11-14 | 0.66 |
| 2024-08-19 | 2024-08-19 | 467.76 |
| 2024-01-23 | 2024-02-12 | 0.02 |
Tasanto - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2026-03-11 | 2026-03-12 | 531.0 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Tasanto, UAB (code 305701983) is a Private Limited Liability Company operating in the wholesale of pharmaceutical and medical goods. In 2025, revenue reached €1.25M, increasing by 35.1% year on year and by 83.1% over two years. Net profit fell to €80.3K from €155.5K in 2024 and €92.3K in 2023, and the profit margin narrowed to 6.4% from 16.8% and 13.5% in the previous two years. Total assets rose to €502.0K in 2025, supported by €379.4K of short-term assets and €122.5K of long-term assets. Equity declined to €90.0K, while liabilities increased to €415.1K, which left the balance sheet more leveraged and the equity ratio at 17.9%. Asset turnover improved to 2.49x, indicating stronger use of the asset base to generate sales. Revenue per employee was €312.6K and profit per employee was €20.1K. Overall, 2025 was a year of strong revenue expansion, but profitability weakened and the capital structure became more debt-dependent.